BioCentury
ARTICLE | Clinical News

Levetiracetam: Phase II data

April 6, 2015 7:00 AM UTC

AgeneBio Inc., Carmel, Ind. Product: Levetiracetam ( AGB101) Business: Neurology Molecular target: Synaptic vesicle protein (SV2A) Description: Low-dose formulation of levetiracetam, a high affinity ...